Application Value Analysis of Metformin Combined with Insulin Degludec Aspart in Patients with Type 2 Diabetes Mellitus Complicated with Pri-mary Liver Cancer
Objective To analyze the application value of metformin combined with insulin degludec aspart in pa-tients with type 2 diabetes mellitus complicated with primary liver cancer.Methods A total of 100 patients with type 2 diabetes mellitus complicated with primary liver cancer admitted to the Department of Oncology of 910th Hospital of Joint Logistics Support Force from August 2021 to July 2023 were selected as the research objects.According to differ-ent treatment methods,they were divided into two groups,50 cases in each group.Both groups underwent ultrasound-guided percutaneous microwave ablation.The control group took metformin orally,and the observation group com-bined with insulin degludec aspart treatment on the basis of the control group.The blood glucose fluctuation,insulin dosage,blood glucose levels and adverse reactions were compared between the two groups.Results After treatment,the average blood glucose fluctuation range and insulin dosage in the observation group were lower than those in the control group,and the average daily blood glucose compliance time was higher than that in the control group,the dif-ferences were statistically significant(all P<0.05).After treatment,there were no significant differences in blood glu-cose levels between the two groups(all P>0.05).Intra-group comparison showed that the levels of fasting blood glu-cose,2-hour postprandial blood glucose and glycated hemoglobin A1c in the two groups after treatment were lower than those before treatment,and the differences were statistically significant(all P<0.05).The incidence of adverse re-actions in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion Metformin+insulin degludec aspart can significantly improve the blood glucose fluctuation,reduce insulin dosage and reduce the incidence of adverse reactions in patients with type 2 diabetes mellitus complicated with primary liver cancer.
Type 2 diabetes mellitusPrimary liver cancerBlood glucoseAdverse reactionsInsulin
维普
万方数据
